MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
11.40
-0.67
-5.55%
After Hours: 11.40 0 0.00% 16:10 12/30 EST
OPEN
12.01
PREV CLOSE
12.07
HIGH
12.80
LOW
11.28
VOLUME
156.20K
TURNOVER
--
52 WEEK HIGH
15.25
52 WEEK LOW
3.350
MARKET CAP
416.44M
P/E (TTM)
-5.0539
1D
5D
1M
3M
1Y
5Y
1D
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares
Reuters · 1h ago
Weekly Report: what happened at CTNM last week (1222-1226)?
Weekly Report · 1d ago
Weekly Report: what happened at CTNM last week (1215-1219)?
Weekly Report · 12/22 10:32
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Contineum Therapeutics, Inc. Class A (CTNM), Xoma (XOMA) and Applied Therapeutics (APLT)
TipRanks · 12/15 14:41
Weekly Report: what happened at CTNM last week (1208-1212)?
Weekly Report · 12/15 10:41
BUZZ-Contineum Therapeutics slides after upsized $90 million stock sale
Reuters · 12/12 16:56
Contineum Therapeutics Shares Fall on $90M Share Offering Pricing
Dow Jones · 12/12 14:39
Contineum Therapeutics stock drops as company prices upsized $90 million offering
Seeking Alpha · 12/12 06:55
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.